Fluidigm's BioMark HD real-time PCR system is designed for researchers who require the sensitivity and throughput needed to study gene expression down to the single-cell level, especially those who have limited amounts of sample or study rare populations of cells.
The system features a number of other important design changes incorporated to
improve performance, lower operating costs, and provide an expanded
applications suite.
The system relies on nanofluidic technology, delivering savings in cost and
time by providing massive parallelism of experiments and an easy-to-use
workflow. By incorporating a new fast thermal cycling protocol, the system
reduces time-to-result by increasing the throughput of the original system
two-fold. Users now have the ability to generate over 50,000 data points in
one day with only one technician. The fast thermal cycling protocol is
compatible with commercially available assays and yields data that is equal
in quality to standard cycling protocol data.
The BioMark HD platform continues to support all the applications of the
original BioMark System, including gene expression, single-cell gene
expression, and genotyping. Using Digital Array chips, the BioMark HD System
performs common digital PCR applications, such as mutation detection, copy
number variation, and absolute quantitation of nucleic acid sequences.
Fluidigm develops, manufactures, and markets proprietary Integrated Fluidic
Circuit (IFC) systems that significantly improve productivity in life
science research. Fluidigm’s IFCs enable the simultaneous performance of
thousands of sophisticated biochemical measurements in extremely minute
volumes. These “integrated circuits for biology” are made possible by
miniaturizing and integrating liquid handling components on a single
microfluidic device (IFC). Fluidigm’s IFC systems, consisting of
instrumentation, software and single-use IFCs, increase throughput, decrease
costs and enhance sensitivity compared to conventional laboratory systems.
Fluidigm products have not been cleared or approved by the Food and Drug
Administration for use as a diagnostic and are only available for research
use.
Fluidigm Corporation
7000 Shoreline Court, Suite 100
South San Francisco, CA 94080
Phone: 1-866-358-4354
Fax: 650-871-7152
http://www.fluidigm.com
